Organic Active Ingredients TRIZ Cases

By targeting MTA-bound PRMT5 in MTAP-null cancer cells, these compounds improve tumor selectivity while limiting myelosuppression and normal tissue effects.

2′-F, 2′-Me, phosphorothioate, and abasic modifications improve nucleic acid stability while preserving target gene inhibition.

Combining CLK/DYRK inhibitors with venetoclax sensitizes resistant leukemia cells, promotes apoptosis, and helps delay relapse.

Novel AMPA receptor PAM compounds tune receptor binding to enhance cognition and synaptic plasticity while lowering convulsant risk.

Controlled-release pαKG microparticles prevent rapid αKG metabolism and diffusion, enabling immune modulation and improved tissue regeneration.

P-gp substrate CB1 blockers with low brain exposure preserve metabolic efficacy in peripheral organs while avoiding CNS side effects.

Targeted pyrazolo[1,5-a]pyridine TRPM3 antagonists address pain and inflammatory hypersensitivity while improving side-effect and pharmacokinetic profiles.

A thin oral film replaces hard-to-swallow lurasidone tablets with rapid saliva dissolution, better taste, and improved compliance.

Rapid centanafadine dosing and flexible monotherapy or add-on use target slow antidepressant onset with effective symptom relief and low adverse events.

Novel Formula I compounds modulate YAP/TEAD binding to reduce target gene expression and produce anti-proliferative effects.

Modified bile acid derivatives activate FXR to address inadequate cognitive therapies and help protect against impairment and cellular senescence.

Species-specific recombinant MG-53 proteins improve membrane repair and wound healing across animals, reducing scarring and supporting tissue regeneration.

Novel compounds tune YAP/TEAD binding to lower target-gene expression and deliver anti-proliferative effects in Hippo pathway diseases.

Pre-dosing DMT with a long-acting tryptamine helps buffer rapid onset, reducing anxiety and disorientation while preserving positive effects.

Defined crystalline salt forms improve TYK2 selectivity over JAK2 and enable PXRD-based solid-state control for safer therapeutic use.

Targeting the HSV helicase-primase complex, cyclic urea thiazolyl compounds improve antiviral potency while reducing adverse effects.

A Monascinol-based composition reduces liver fat, AST and ALT while improving gut microbiota for safer NAFLD treatment.

Branched hydrophobic tails improve ionization at endosomal pH and membrane fusion, boosting lipid nanoparticle delivery of mRNA and siRNA.

A minoxidil powder blended with dry shampoo supports hair growth while absorbing scalp oil, avoiding residue buildup and daily washing.

Covalent CPP-melphalan conjugates enable eye-drop delivery to the posterior ocular segment, improving absorption without intraocular injection.

Gastro-resistant tablets release bile acid sequestrants in the ileum and colon to reduce diarrhea while limiting upper GI side effects.

Ion-exchange resin complexes slow oral drug release for 8-24 hours while reducing extraction in non-gastric media to deter tampering and abuse.

Salt and prodrug forms of indoximod improve solubility, absorption, and plasma exposure to overcome its non-linear oral pharmacokinetics.

A narrow DHEAS alkanoyl ester range treats atherosclerosis and valvular calcification while reducing oxidative stress, toxicity, and hormonal effects.

A triazole-glucosamine formulation inhibits mycobacterial growth, including resistant strains, while improving stability and bioavailability.

Interconnected channels in a 3D-printed solid dosage form improve fluid percolation for more predictable drug release and rapid disintegration.

Dual CYP17A1 and AKT inhibition addresses androgen-AR and PI3K/AKT escape pathways to improve prostate cancer treatment response.

A self-emulsifying capsule delivers poorly water-soluble actives in clear beverages, improving bioavailability without consumer mixing.

A Formula IV compound protects vascular endothelium during thrombolytic or anticoagulant therapy, reducing hemorrhage and blood-brain barrier damage.

A Monascus pilosus fermented composition supports weight loss by shifting gut microbiota toward beneficial bacteria and lowering the Firmicutes ratio.

Genetic screening of mGluR network alterations guides fasoracetam use to reduce tics and improve ADHD- and OCD-related symptoms.

Crystalline dihydrochloride hydrate forms improve omecamtiv mecarbil solubility, stability, and low hygroscopicity for heart failure formulations.

Selective hydroxamates target Nav1.7 and Nav1.8 channels to relieve neuropathic pain while reducing adverse effects from non-selective blockers.

Aryl-piperidine derivatives inhibit tankyrase, suppress β-catenin, stabilize AXIN2, and improve anticancer activity with fewer side effects.

Selective aryl pyridine blockade of Nav1.7 and Nav1.8 targets pain pathways to relieve neuropathic pain with fewer adverse effects.

Acetone, methanol, salt separation, and filtration purify PS-enriched brain phospholipids without chloroform residues or silica gel chromatography.

An MPA suspension with docusate sodium and polyethylene glycol improves heat-stable shelf life and syringeability for long-acting subcutaneous contraception.

A prodrug of HMS5552 stays stable in gastric fluid, then hydrolyzes in the small intestine to improve absorption and diabetes treatment.

Novel heteroaromatic carboxamides improve plasma kallikrein inhibition while boosting selectivity, metabolic stability, and safety.

Changing the octahydrothienoquinoline drug salt from hydrochloride to succinate improves hygroscopicity, crystallinity, and storage stability.

An oral Monascinol composition reduces liver fat and AST/ALT while improving gut microbiota balance in obesity-related NAFLD.

Selective amide blockers target Nav1.7 and Nav1.8 to relieve neuropathic pain while reducing adverse effects from non-selective sodium channel inhibition.

Antibody-drug conjugates direct glucocorticoids to antigen-expressing cells, limiting non-target toxicity while maintaining treatment efficacy.

Multiple butylphthalide salt forms improve stability and bioavailability while supporting neuroprotection in ischemic and degenerative disorders.

Targeting CCL1 in Kupffer cells helps inhibit hepatic fibrosis while reducing the side effects of non-specific liver treatments.

A maleimide or cyclooctyne amino acid linker improves ADC blood stability, lowers polymer formation, and enables enzymatic toxin release.

Using galactose and fucose as monosaccharides promotes faster re-epithelialization, shortens healing time, and helps minimize scarring.

Specific CYP2E1 inhibitors target chronic inflammatory microenvironments to curb oxidative stress, tumor progression, and related IMDs.

ABP combinations target extracellular Ras without HLA restriction, while 3D tumor models improve detection and therapy testing on viable cells.

Lowering glycated chitosan below 420 kDa enables sterile filtration and purification while preserving dendritic cell CD40 activation.